Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-09. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Mechanotaxis refers to the directed movement of cell motility via mechanical cues (e.g., fluidic shear stress, substrate stiffness gradients, etc.). In response to fluidic shear stress, for example, cells have been shown to migrate in the direction of the fluid flow. Mechanotaxis is critical in many normal biological processes in animals, such as gastrulation, inflammation, and repair in response to a wound, as well as in mechanisms of diseases such as tumor metastasis. A subset of mechanotaxis - termed durotaxis - refers specifically to cell migration guided by gradients in substrate rigidity (i.e. stiffness). The observation that certain cell types seeded on a substrate rigidity gradient migrate up the gradient (i.e. in the direction of increasing substrate stiffness) was first reported by Lo et al. The primary method for creating rigidity gradients for cells (e.g., in biomaterials) consists of altering the degree of cross-linking in polymers to adjust substrate stiffness. Alternative substrate rigidity gradients include micropost array gradients, where the stiffness of individual microposts is increased in a single, designed direction.
Kenney, Padraic. 1989: Democratic Revolutions at the Cold War's End: A Brief History with Documents (2009) covers Poland, the Philippines, Chile, South Africa, Ukraine, and China Leffler, Melvyn P. For the Soul of Mankind: The United States, the Soviet Union, and the Cold War (2007) pp 338–450. Mann, James. The Rebellion of Ronald Reagan: A History of the End of the Cold War (2010). popular Matlock, Jack F. Autopsy on an Empire (1995) online by US ambassador to Moscow Matlock, Jack F. Reagan and Gorbachev : how the Cold War ended (2004) online Powaski, Ronald E. The Cold War: The United States and the Soviet Union, 1917–1991 (1998) Romero, Federico. "Cold War historiography at the crossroads." Cold War History 14.4 (2014): 685–703. online Shultz, George P. Turmoil and Triumph: My Years as Secretary of State (1993), a primary source Wilson, James Graham. The Triumph of Improvisation: Gorbachev's Adaptability, Reagan's Engagement, and the End of the Cold War (2014) Wohlforth, William C. "Realism and the End of the Cold War." International Security 19.3 (1994): 91–129. online Zubok, Vladislav M. "Gorbachev and the End of the Cold War: Perspectives on History and Personality," Cold War History (2002) 2:2, 61–100, DOI: 10.1080/713999954 Zubok, Vladislav M. A failed empire: the Soviet Union in the Cold War from Stalin to Gorbachev (2009). online Archived 2020-09-19 at the Wayback Machine
==== PEG treatment ==== The purpose of the polyethylene glycol is to remove water from the wood while simultaneously bulking the deteriorated wood cells. PEG is applied to the surface, either by spraying or immersing the object in a solution of PEG in water. Over the course of the treatment, PEG is slowly increased in concentration, pushing out the excess water, coating the interior walls of the wood cells with PEG, which, depending on the molecular weight selected, will provide support once the artifact is dried. PEG compounds with different molecular weights may be used depending on the wood type, level of deterioration, and scope of project. The PEG treatment is often paired with vacuum freeze-drying, as the eutectic point of most PEG solutions is below the freezing point of water. This allows the "free" waterlogging water to sublimate in the process of freeze-drying, which minimizes damage to the wood by preventing ice from forming within the cells and expanding, causing more shrinking and warping. Some artifacts are too large to fit in a commercially available freeze-drier (see the treatment for Vasa or Mary Rose or the Bremen cog).
The enzyme characterised from Azotobacter vinelandii hydrolyses the nucleotide, nicotinamide mononucleotide, to give nicotinate mononucleotide and ammonia. Manufacture of nicotinamide mononucleotide for use as a pharmaceutical drug has been studied and in this context its degradation by nicotinamide-nucleotide amidase is undesirable, so means to down-regulate the enzyme or remove its associated gene have been sought. This enzyme is a hydrolase, one acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is nicotinamide-D-ribonucleotide amidohydrolase. Other names in use include NMN deamidase, nicotinamide mononucleotide deamidase, and nicotinamide mononucleotide amidohydrolase.
Sources: en.wikipedia.org
Zverev's first ATP event of the year was the 2016 Australian Open, where he had a difficult draw against world No. 2 Andy Murray and was only able to win six games in his opening match. He bounced back at the Open Sud de France, reaching the semifinals in the singles event and his second career final with his brother in the doubles event. During the singles event, he upset No. 13 Marin Čilić, the highest-ranked player he had defeated in an official match at the time. Zverev then produced a strong result at the Indian Wells Masters, where he defeated two top 30 players. In the fourth round, he nearly upset No. 5 Rafael Nadal. Zverev had a match point while he was serving for the final set, but missed a routine forehand volley and then proceeded to lose 14 of the remaining 15 points in the match. He commented on the match point that, "I missed probably the easiest shot I had the whole match." Back in Europe, Zverev was able to recover as he reached his first ATP singles final at the Open de Nice Côte d'Azur, finishing runner-up to No. 15 Dominic Thiem, the top seed and defending champion. Thiem also defeated him in the third round of the French Open.
== Research == Ogston studied potentiometric titration of amino acids in non-aqueous solvents. He was particularly interested in sinovial fluid, and fibrous proteins. More generally, he worked on the use of physico-chemical methods to study the size, weight, and structure of molecules, such as ultracentrifugation, which he applied to insulin, for example, and electrophoresis. In this context he made many improvement to equipment used for studying the physical chemistry of proteins. For example, he devised a novel type of apparatus for measuring viscosity. He made many studies of enzymes such as peroxidase and creatine phosphotransferase. He contributed to the general field of enzyme kinetics by studying activation and inhibition. He made a sceptical study of the suggestions of a repetitive structure of proteins made by Bergmann and Niemann and by Wrinch that were widely discussed in the 1940s.
The geography of Colombia is characterized by its six main natural regions that present their unique characteristics, from the Andes mountain range region; the Pacific Coastal region; the Caribbean coastal region; the Llanos (plains); the Amazon rainforest region; to the insular area, comprising islands in both the Atlantic and Pacific oceans. It shares its maritime limits with Costa Rica, Nicaragua, Honduras, Jamaica, Haiti, and the Dominican Republic. Colombia is bordered to the northwest by Panama, to the east by Venezuela and Brazil, and to the south by Ecuador and Peru; it established its maritime boundaries with neighboring countries through seven agreements on the Caribbean Sea and three on the Pacific Ocean. It lies between latitudes 12°N and 4°S and between longitudes 67° and 79°W. East of the Andes lies the savanna of the Llanos, part of the Orinoco River basin, and in the far southeast, the jungle of the Amazon rainforest. Together these lowlands make up over half Colombia's territory, but they contain less than 6% of the population. To the north the Caribbean coast, home to 21.9% of the population and the location of the major port cities of Barranquilla and Cartagena, generally consists of low-lying plains, but it also contains the Sierra Nevada de Santa Marta mountain range, which includes the country's tallest peaks (Pico Cristóbal Colón and Pico Simón Bolívar), and the La Guajira Desert. By contrast the narrow and discontinuous Pacific coastal lowlands, backed by the Serranía de Baudó mountains, are sparsely populated and covered in dense vegetation.
== Career and research == In 1984, Drucker began his research career at Massachusetts General Hospital and Harvard Medical School, studying molecular endocrinology in the lab of Professor Joel Habener with the support from a Medical Research Council of Canada Centennial Fellowship. Drucker’s independent discoveries in Boston included the demonstration that proglucagon could be cleaved into multiple glucagon-like peptides, including several distinct isoforms of GLP-1. He then discovered that the truncated form of GLP-1(7-37) directly stimulated cyclic AMP formation, insulin secretion, and insulin gene expression; notably, it did so only when glucose levels were elevated.
Molybdenum is the 54th most abundant element in the Earth's crust with an average of 1.5 parts per million and the 25th most abundant element in the oceans, with an average of 10 parts per billion; it is the 42nd most abundant element in the Universe. The Soviet Luna 24 mission discovered a molybdenum-bearing grain (1 × 0.6 μm) in a pyroxene fragment taken from Mare Crisium on the Moon. The comparative rarity of molybdenum in the Earth's crust is offset by its concentration in a number of water-insoluble ores, often combined with sulfur in the same way as copper, with which it is often found. Though molybdenum is found in such minerals as wulfenite (PbMoO4) and powellite (CaMoO4), the main commercial source is molybdenite (MoS2). Molybdenum is mined as a principal ore and is also recovered as a byproduct of copper and tungsten mining. The world's production of molybdenum was 250,000 tonnes in 2011, the largest producers being China (94,000 t), the United States (64,000 t), Chile (38,000 t), Peru (18,000 t) and Mexico (12,000 t). The total reserves are estimated at 10 million tonnes, and are primarily concentrated in China (4.3 Mt), the US (2.7 Mt) and Chile (1.2 Mt). By continent, 93% of the world's molybdenum production is distributed approximately evenly among North America, South America (mainly Chile), and China. Europe and the rest of Asia (mostly Armenia, Russia, Iran and Mongolia) produce the remainder.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.